37D High Speed Automatic Rotary Dd Punch Double Slide Bath Salt Bomb Pill Tablet Press Machine

Name: Zp31/33/35/37D High Speed Automatic Rotary Dd Punch Double Slide Bath Salt Bomb Pill Tablet Press Machine
Brand: Jining Factop International Trade Co., Ltd.
SKU: 1923181526

Shandong, ChinaJining Factop International Trade Co., Ltd.

US$8,000.00

1-4 Sets

US$7,000.00

5+ Sets

Product profile

Customization

Available

Automation Level

Fully Automatic

Capacity

120000 Tablet/Hour

Model NO.

ZP420

Certification

CE Certified, GMP Compliant, ISO Certified

Tablet Shape

Oval, Rectangular, Round, Square

Warranty

1 Year

Finished Dosage Form

Tablet, Pill

Precision

High Precision

Voltage

380V

Computerized

Customized

Condition

New

Type

Pharmaceutical Machinery

After-Sales Service

Have

Transport Package

Wooden Packing

Specification

Food grade material

Trademark

Origin

China

HS Code

8479109000

Production Capacity

100 Set/Week

Company profile

Importers and ExportersHigh Repeat Buyers ChoiceFast DeliveryMinor Customization

Jining Factop International Trade Co., Ltd.

Shandong, China

Business Type: Manufacturer/Factory, Trading CompanyExport Year: 2014-06-20Nearest Port: Shanghai, NingboAverage Response Time: ≤0.53hTerms of Payment: T/T, Western Union, Money GramInternational Commercial Terms(Incoterms): FOB, EXW, CFR, CIF, DDP, DAP, FCA

AI-Powered supplier vetting

SummaryThe supplier manufactures pharmaceutical and packaging machinery, including blister packing, sugar coating, tablet counting, and related production equipment. Its products are exported to the United States, Europe, the Middle East, Southeast Asia, and North America, with exports representing 51%–70% of total sales and eight years of exporting experience. Production and delivery indicators are partially positive, including peak- and off-season lead times within 15 workdays and stated quality assurance with raw-material traceability. However, the supplier has no documented corrective-action or complaint-handling procedures, no supplier-service assessment records, no listed management-system certification, no overseas service infrastructure, no inventory service capability, and no new products launched during the previous year. R&D and design resources appear limited, with one R&D engineer and minor customization capability. Customer retention is reported at 50%–80%, but specific customer cases are not provided.

Supplier typeThe supplier is a manufacturer and developer of pharmaceutical production and packaging machinery, including blister packing, sugar coating, tablet counting, and powder-to-tablet/capsule equipment. It sells domestically and exports to the United States, Europe, the Middle East, Southeast Asia, and North America, with eight years of export experience and stated self-operated import/export rights.

CertificationsThe supplier states that its tablet-press digital control system supports alignment with cGMP and FDA requirements, but the available information does not identify a certification held by the supplier. Supplier management-system certification is explicitly listed as NIL, so no formal certification holding is evidenced.

After-Sales capabilityThe supplier cites good after-sales service as a company tenet and accepts multiple quotation terms, but it has no written corrective/preventive-action procedures, no written customer-complaint procedures or records, and no written service-capability assessment procedure. It also reports no overseas agents or branches, overseas warehouse, showroom, inventory capability, or overseas service countries, indicating limited documented and local service infrastructure.

R&D capabilityThe supplier reports integrated development and production capabilities and describes high-tech machinery development, but it has only one R&D engineer, one year of total R&D-engineer experience is reported, and no new products were launched during the previous year. These explicit indicators show limited recent innovation output.

Production capacityThe supplier reports integrated manufacturing of several pharmaceutical machinery categories, exports representing 51%–70% of sales, annual production output above the stated threshold, and lead times within 15 workdays in both peak and off-season periods. Quality assurance and raw-material traceability are reported, although finished products are randomly inspected and checked by packing staff, which limits the evidence of a robust final-inspection system.

Customization capabilityThe supplier explicitly offers minor customization. No evidence is provided of moderate or extensive engineering customization, so the demonstrated capability is limited to minor modifications.